Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-RAMLER, Lukas C; AGUS, David B; MARTIN, Jason et al.Cancer research (Baltimore). 2000, Vol 60, Num 21, pp 6134-6141, issn 0008-5472Article

Molecular cytogenetic studies of a serially transplanted primary prostatic carcinoma xenograft (CWR22) and four relapsed tumorsKOCHERA, M; DEPINET, T. W; PRETLOW, T. P et al.The Prostate. 1999, Vol 41, Num 1, pp 7-11, issn 0270-4137Article

Development of albumin-binding doxorubicin pro drugs that are cleaved by prostate-specific antigenKRATZ, Felix; MANSOUR, Ahmed; SOLTAU, Jens et al.Archiv der Pharmazie (Weinheim). 2005, Vol 338, Num 10, pp 462-472, issn 0365-6233, 11 p.Article

Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrayslMOUSSES, Spyro; BUBENDORF, Lukas; FERHLE, William et al.Cancer research (Baltimore). 2002, Vol 62, Num 5, pp 1256-1260, issn 0008-5472Article

Growth inhibition of prostate cancer xenografts by halofuginoneGAVISH, Zohar; PINTHUS, Jehonathan H; BARAK, Vivian et al.The Prostate. 2002, Vol 51, Num 2, pp 73-83, issn 0270-4137Article

Ligand responsiveness in human prostate cancer : Structural analysis of mutant androgen receptors from LNCaP and CWR22 tumorsMCDONALD, S; BRIVE, L; AGUS, D. B et al.Cancer research (Baltimore). 2000, Vol 60, Num 9, pp 2317-2322, issn 0008-5472Article

Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft modelsAGUS, D. B; SCHER, H. I; HIGGINS, B et al.Cancer research (Baltimore). 1999, Vol 59, Num 19, pp 4761-4764, issn 0008-5472Article